✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Jagsonpal Pharmaceuticals Ltd.

JAGSNPHARM

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹1,439 Cr.
P/E
23.23

Jagsonpal Pharmaceuticals Ltd.

  • Jagsonpal Pharma
  • Syncom Formulations
  • Bliss GVS Pharma

FAQs on Jagsonpal Pharmaceuticals Ltd. Shareprice

Jagsonpal Pharma has given better returns compared to its competitors.
Jagsonpal Pharma has grown at ~39.5% over the last 8yrs while peers have grown at a median rate of 28.28%

Jagsonpal Pharma is not expensive.
Latest PE of Jagsonpal Pharma is 23.23, while 3 year average PE is 38.47.
Also latest EV/EBITDA of Jagsonpal Pharma is 23.19 while 3yr average is 28.73.

View FAQ's On Business

Growth Table

  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma

Balance Sheet

  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma

Cash Flow

  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma

Quarterly Results

  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Jagsonpal Pharmaceuticals Ltd. Financials

Balance sheet of Jagsonpal Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Jagsonpal Pharma is increasing.
Latest net debt of Jagsonpal Pharma is -₹159.24 Crs as of Sep-25.
This is greater than Mar-25 when it was -₹257.46 Crs.

Yes, profit is increasing.
The profit of Jagsonpal Pharma is ₹61.94 Crs for TTM, ₹55.36 Crs for Mar 2025 and ₹22.46 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Jagsonpal Pharma latest dividend payout ratio is 29.98% and 3yr average dividend payout ratio is 45.95%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech